KCAS Bio

KCAS Bio is a leading contract research organization (CRO) that has been at the forefront of bioanalytical innovation since 1979. Founded with a vision to accelerate drug development, the organization recognized that scientific innovators needed a partner who could combine deep technical expertise with regulatory rigor to bring life-changing therapeutics to market faster. What began as a specialized bioanalytical laboratory has evolved into a global CRO with facilities across the United States and Europe, serving both large pharmaceutical companies and emerging biotech sponsors.

Today, KCAS Bio stands as a trusted partner in the global biopharmaceutical industry, having supported more than 315 approved drugs and developed over 6,200 proprietary and non-proprietary assays. The company's comprehensive capabilities span bioanalytical services, biomarker testing, immunogenicity assessment, and molecular biology testing across therapeutic areas from oncology and immunology to metabolic and neurological disorders. Their team of expert scientists operates state-of-the-art BSL-2 facilities with 24/7 monitoring, maintaining an exemplary regulatory record with more than 20 FDA audits without major findings. By combining scientific excellence, regulatory compliance, and client partnership, KCAS Bio continues to drive the development of breakthrough therapies that improve patients' lives worldwide.